Search Results - "Malicot, K Le"

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial by Bruzzi, M., Auclin, E., Lo Dico, R., Voron, T., Karoui, M., Espin, E., Cianchi, F., Weitz, J., Buggenhout, A., Malafosse, R., Denimal, F., Le Malicot, K., Vernerey, D., Douard, R., Emile, J. F., Lepage, C., Laurent-Puig, P., Taieb, J.

“…Background Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain unclear. The objective of the study was to assess…”
Get full text

Fibrates and microvascular complications in diabetes--insight from the FIELD study by Ansquer, J C, Foucher, C, Aubonnet, P, Le Malicot, K

“…Fibrates are widely prescribed lipid-lowering drug in the treatment of dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative…”
Get more information

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial by Touchefeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Phelip, J. M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O.

“…Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and…”
Get full text

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort by Walter, T, Tougeron, D, Baudin, E, Le Malicot, K, Lecomte, T, Malka, D, Hentic, O, Manfredi, S, Bonnet, I, Guimbaud, R, Coriat, R, Lepère, C, Desauw, C, Thirot-Bidault, A, Dahan, L, Roquin, G, Aparicio, T, Legoux, J.-L, Lombard-Bohas, C, Scoazec, J.-Y, Lepage, C, Cadiot, G

“…Abstract Background Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging…”
Get full text

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients by Taieb, J, Balogoun, R, Le Malicot, K, Tabernero, J, Mini, E, Folprecht, G, Van Laethem, J-L, Emile, J-F, Mulot, C, Fratté, S, Levaché, C-B, Saban-Roche, L, Thaler, J, Petersen, L N, Bridgewater, J, Perkins, G, Lepage, C, Van Cutsem, E, Zaanan, A, Laurent-Puig, P

“…RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial…”
Get full text

Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies by Salvatore, L., Bria, E., Sperduti, I., Hinke, A., Hegewisch-Becker, S., Aparicio, T., Le Malicot, K., Boige, V., Koeberle, D., Baertschi, D., Dietrich, D., Tortora, G., Arnold, D.

Get full text

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial by Gaston Mathe, Y, Martin-Lannerée, S, Vazart, C, Fontaine, K, Mulot, C, Caumont, A, Montestruc, F, Le Malicot, K, Lepage, C, Taieb, J, Laurent-Puig, P

Get full text

Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study by Lapeyre-Prost, A, Pernot, S, Sigrand, J, Mary, F, Le Malicot, K, Aparicio, T, Dahan, L, Caroli-Bosc, F-X, Lecomte, T, Racine Doat, S, Marthey, L, Desrame, J, Lepage, C, Taieb, J

Get full text

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8 by Laurent-Puig, P., Marisa, L., Ayadi, M., Blum, Y., Balogoun, R., Pilati, C., Le Malicot, K., Lepage, C., Emile, J.F., Salazar, R., Aust, D., Duval, A., Selves, J., Guenot, D., Milano, G., Seitz, J.-F., Taieb, J., Boige, V., de Reyniès, A.

Get full text

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens by du Rusquec, P., Guimbaud, R., Le Malicot, K., Gornet, J.-M., Nguyen, S., Lecomte, T., Khemissa-Akouz, F., Perrier, H., Bouché, O., Paoletti, X., Le Tourneau, C.

“…Precision medicine trials disrupted the paradigm of randomized controlled trials in large populations. Patient selection may be based on molecular alterations…”
Get full text

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy by Gallois, C., Taieb, J., Le Corre, D., Le Malicot, K., Tabernero, J., Mulot, C., Seitz, J.-F., Aparicio, T., Folprecht, G., Lepage, C., Mini, E., Van Laethem, J.-L., Emile, J.F., Laurent-Puig, P.

Get full text

Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial by Aparicio, T., Bennouna, J., Le Malicot, K., Boige, V., Taieb, J., Bouche, O., Francois, E., Phelip, J-M., Borel, C., Faroux, R., Dahan, L., Bachet, J-B., Egreteau, J., Kaminsky-Forrett, M-C., Gornet, J-M., Cojocarasu, O., Gasmi, M., Guerin-Meyer, V., Ghiringhelli, F., Lepage, C.

Get full text

2305 Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part by Hebbar, M, Heurgue-Berlot, A, Boige, V, Le Malicot, K, Bernard-Chabert, B, Marcus, C, Dharancy, S, Sergent, G, Perarnau, J.M, Ehrhard, F, Ollivier-Hourmand, I, Vergniol, J, Michel, P, Edeline, J, Rinaldi, Y, Seitz, J.F, Lepage, C, De Baere, T

Get full text

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset by Blons, H., Emile, J.F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J.L., Thaler, J., Bridgewater, J., Nørgård-Petersen, L., Van Cutsem, E., Lepage, C., Zawadi, M.A., Salazar, R., Laurent-Puig, P., Taieb, J.

“…The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III…”
Get full text

567P Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study by Bergen, E.S., Canton, C., Boulin, M., Le Malicot, K., Bennouna, J., Gonzalez, D., Mineur, L., Coriat, R., Bouche, O., Lepage, C., Taieb, J.

Get full text

629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2) by Tougeron, D., Hautefeuille, V., Zaanan, A., Le Malicot, K., Moulin, V., Cohen, R., Lecomte, T., Aleba, A., Viaud, J., Lam, Y.H., Etienne, P.L., Mosser, L., Ramdani, M., Le Sourd, S., Poisson Ligeza, C., Goujon, G., Lepage, C., Bouche, O.

Get full text

391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials by Bergen, E.S., Christou, N., Le Malicot, K., Canton, C., Di Bartolomeo, M., Galli, F., Labianca, R., Shi, Q., Alberts, S.R., Goldberg, R.M., Lepage, C., Sinicrope, F.A., Taieb, J.

Get full text

OC-0277 Capecitabine or 5-fluorouracil infusion with radiotherapy of anal cancers in the FFCD-Anabase cohort by Delhiat, A., Lemanski, C., Le-Malicot, K., Saint, A., Rivin del Campo, E., Pommier, P., Regnault, P., Baba-Hamed, N., Ronchin, P., Quéro, L., Ménager-Tabourel, E., Diaz, O., Lièvre, A., Tougeron, D., Mornex, F., Larrouy, A., Barbier, N., Vendrely, V.

Get full text

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma by Tougeron, D., Dahan, L., El Hajbi, F., Le Malicot, K., Evesque, L., Aparicio, T., Bouche, O., Bonichon Lamichhane, N., Chibaudel, B., Angelergues, A., A. bodere, Phelip, J.M., Mabro, M., Artru, P., Louvet, C.

Get full text

LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD by Zaanan, A., Bouche, O., de la Fouchardiere, C., Samalin-Scalzi, E., Le Malicot, K., Pernot, S., Artru, P., Ly Lebrun, V., Aldabbagh, K., Khemissa Akouz, F., Castanie, H., Laly, M., Botsen, D., Muller, M., Roth, G., Lecomte, T., Phelip, J.M., Lepage, C., Louvet, C.

Get full text